Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, Accenture plc insiders sold a net $4.6M of stock across 662 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-27.
13 earlier Form 4 trades (code P or S) here by this insider (13 sales), the last on Oct 22, 2025.
The trade is 206.5% of the 2,296 shares held after it.
2 other insiders sold within 30 days.
963 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Co-CEO Asia Pacific Sekido Ryoji sold about $1.2M of ACN on Oct 22, 2026, the largest insider sale at the company since 2025; 2 other insiders sold within 30 days and 963 funds added in the latest 13F quarter.
13 earlier Form 4 trades (code P or S) here by this insider (13 sales), the last on Oct 22, 2025.
The trade is 92.3% of the 1,194 shares held after it.
2 other insiders sold within 30 days.
963 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Co-CEO Asia Pacific Sekido Ryoji sold about $270.3K of ACN on Oct 22, 2026; 2 other insiders sold within 30 days and 963 funds added in the latest 13F quarter.
27 earlier Form 4 trades (code P or S) here by this insider (27 sales), the last on Feb 3, 2026.
The trade is 8.3% of the 9,820 shares held after it.
2 other insiders sold within 30 days.
963 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Accounting Officer Burgum Melissa A sold about $202.8K of ACN under a 10b5-1 plan on Oct 22, 2026; 2 other insiders sold within 30 days and 963 funds added in the latest 13F quarter.
6 earlier Form 4 trades (code P or S) here by this insider (6 sales), the last on Oct 8, 2026.
The trade is 0.0% of the 12,555 shares held after it.
2 other insiders sold within 30 days.
963 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Operating Officer Hogan Catherine Kiernan sold about $211 of ACN under a 10b5-1 plan on Oct 12, 2026; 2 other insiders sold within 30 days and 963 funds added in the latest 13F quarter.
6 earlier Form 4 trades (code P or S) here by this insider (6 sales), the last on Oct 8, 2026.
The trade is 1.8% of the 12,336 shares held after it.
2 other insiders sold within 30 days.
963 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Operating Officer Hogan Catherine Kiernan sold about $46.7K of ACN under a 10b5-1 plan on Oct 12, 2026; 2 other insiders sold within 30 days and 963 funds added in the latest 13F quarter.
662 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Nobody has filed for crossing 5%. That is a fact, not missing data.
ACN planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
Burgum Melissa A
Filed 2026-10-22
$202.8K
RYOJI SEKIDO
Filed 2026-10-22
$1.4M
Hogan Catherine Kiernan
Filed 2026-10-13
$150.0K
Hogan Catherine Kiernan
Filed 2026-10-08
$261.0K
Unruch Joel
Filed 2026-07-30
$1.8M
ACN mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Genter Dividend Income Fund
$2.0M position · as of 2026-07-31
4.0%
Monarch Dividend Plus Index ETF
$2.2M position · as of 2026-05-31
3.6%
EuroPac International Value Fund
$5.8M position · as of 2026-07-31
2.9%
Monteagle Enhanced Equity Income Fund
$374.1K position · as of 2026-05-31
2.8%
ALPS | OShares U.S. Quality Dividend ETF
$20.9M position · as of 2026-05-31
2.8%
VictoryShares Free Cash Flow ETF
$211.6M position · as of 2026-06-30
2.7%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Executive pay vs shareholder return · Ms. Sweet
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$29.6M
$16.6M
$6.5M
+17%
+151%
2024
$24.9M
$19.7M
$7.5M
+51%
+105%
2023
$31.6M
$28.9M
$9.7M
+41%
+48%
2022
$33.7M
$28.9M
$11.1M
+23%
+11%
2021
$23.1M
$37.4M
$9.2M
+42%
+29%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $4.6M sold by insiders over 180 days, 963 funds added last quarter, 3 House member(s) bought in 12 months, disclosed weeks after the trade, $3.8M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$74.2B
four quarters, 2025-09-01 to 2026-08-31
Revenue, TTM ACN
FY Aug 2026
$74.2B
FY Aug 2025
$69.7B
FY Aug 2024
$64.9B
FY Aug 2023
$64.1B
FY Aug 2022
$61.6B
Aug 2026
$18.7B
May 2026
$18.7B
Feb 2026
$18.0B
Nov 2025
$18.7B
Aug 2025
$17.6B
May 2025
$17.7B
Feb 2025
$16.7B
Nov 2024
$17.7B
At each fiscal year end
Single quarter
Net margin, TTM
+11.3%
net income over revenue, 2025-09-01 to 2026-08-31
Net margin, TTM ACN
FY Aug 2026
+11.3%
FY Aug 2025
+11.0%
FY Aug 2024
+11.2%
FY Aug 2023
+10.7%
FY Aug 2022
+11.2%
Aug 2026
+10.7%
May 2026
+12.5%
Feb 2026
+10.1%
Nov 2025
+11.8%
Aug 2025
+8.0%
May 2025
+12.4%
Feb 2025
+10.7%
Nov 2024
+12.9%
At each fiscal year end
Single quarter
Free cash flow, TTM
$11.6B
operating cash flow minus capex, 2025-09-01 to 2026-08-31
Free cash flow, TTM ACN
FY Aug 2026
$11.6B
FY Aug 2025
$10.9B
FY Aug 2024
$8.6B
FY Aug 2023
$9.0B
FY Aug 2022
$8.8B
Aug 2026
$2.8B
May 2026
$3.6B
Feb 2026
$3.7B
Nov 2025
$1.5B
Aug 2025
$3.8B
May 2025
$3.5B
Feb 2025
$2.7B
Nov 2024
$870.3M
At each fiscal year end
Single quarter
Debt to equity
0.32x
long-term 2026-08-31 plus current 2026-08-31; equity 2026-08-31
Debt to equity ACN
FY Aug 2026
0.32x
FY Aug 2025
0.17x
FY Aug 2024
0.04x
FY Aug 2023
0.01x
FY Aug 2022
0.00x
Aug 2026
0.32x
May 2026
0.16x
Feb 2026
0.16x
Nov 2025
0.17x
Aug 2025
0.17x
May 2025
0.17x
Feb 2025
0.18x
Nov 2024
0.18x
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
1.22x
TTM operating cash flow over long-term 2026-08-31 plus current 2026-08-31
Cash flow to debt ACN
FY Aug 2026
1.22x
FY Aug 2025
2.23x
FY Aug 2024
8.91x
FY Aug 2023
64.40x
FY Aug 2022
173.26x
Aug 2026
1.22x
May 2026
2.56x
Feb 2026
2.54x
Nov 2025
2.35x
Aug 2025
2.23x
May 2025
2.13x
Feb 2025
2.02x
Nov 2024
1.87x
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
+26.7%
TTM net income over average of 2025-08-31 and 2026-08-31
Return on equity ACN
FY Aug 2026
+26.7%
FY Aug 2025
+25.8%
FY Aug 2024
+26.9%
FY Aug 2023
+28.8%
FY Aug 2022
+33.0%
Aug 2026
+26.7%
May 2026
+24.9%
Feb 2026
+25.3%
Nov 2025
+25.3%
Aug 2025
+25.8%
May 2025
+27.3%
Feb 2025
+27.3%
Nov 2024
+27.1%
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+12.0%
TTM net income over average of 2025-08-31 and 2026-08-31
Return on assets ACN
FY Aug 2026
+12.0%
FY Aug 2025
+12.7%
FY Aug 2024
+13.6%
FY Aug 2023
+14.0%
FY Aug 2022
+15.2%
Aug 2026
+12.0%
May 2026
+11.8%
Feb 2026
+12.1%
Nov 2025
+12.2%
Aug 2025
+12.7%
May 2025
+13.5%
Feb 2025
+13.8%
Nov 2024
+13.6%
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
+29.1%
operating income after a 25.1% effective tax rate, over long-term 2026-08-31 plus current 2026-08-31 plus average of 2025-08-31 and 2026-08-31 minus cash
Return on invested capital ACN
FY Aug 2026
+29.1%
FY Aug 2025
+29.3%
FY Aug 2024
+35.0%
FY Aug 2023
+43.3%
FY Aug 2022
+55.4%
Aug 2026
+29.1%
May 2026
+29.8%
Feb 2026
+29.4%
Nov 2025
+29.2%
Aug 2025
+29.3%
May 2025
+30.3%
Feb 2025
+29.4%
Nov 2024
+30.3%
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
+23.7%
operating income (EBIT proxy) over average of 2025-08-31 and 2026-08-31 minus current liabilities
Return on capital employed ACN
FY Aug 2026
+23.7%
FY Aug 2025
+24.9%
FY Aug 2024
+27.3%
FY Aug 2023
+28.0%
FY Aug 2022
+32.7%
Aug 2026
+23.7%
May 2026
+23.1%
Feb 2026
+23.4%
Nov 2025
+23.2%
Aug 2025
+24.9%
May 2025
+26.2%
Feb 2025
+26.1%
Nov 2024
+25.9%
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
18.23x
close 2026-10-26 over four quarters of diluted EPS, 2025-09-01 to 2026-08-31
P/E, trailing ACN
FY Aug 2026
13.99x
FY Aug 2025
21.40x
FY Aug 2024
29.92x
FY Aug 2023
30.06x
FY Aug 2022
26.93x
Aug 2026
13.99x
May 2026
14.94x
Feb 2026
17.09x
Nov 2025
20.66x
Aug 2025
21.40x
May 2025
25.22x
Feb 2025
28.78x
Nov 2024
30.40x
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
n/a
no share count filed
Enterprise value ACN
FY Aug 2026
n/a
FY Aug 2025
n/a
FY Aug 2024
n/a
FY Aug 2023
n/a
FY Aug 2022
n/a
Aug 2026
n/a
May 2026
n/a
Feb 2026
n/a
Nov 2025
n/a
Aug 2025
n/a
May 2025
n/a
Feb 2025
n/a
Nov 2024
n/a
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
n/a
no share count filed
FCF yield ACN
FY Aug 2026
n/a
FY Aug 2025
n/a
FY Aug 2024
n/a
FY Aug 2023
n/a
FY Aug 2022
n/a
Aug 2026
n/a
May 2026
n/a
Feb 2026
n/a
Nov 2025
n/a
Aug 2025
n/a
May 2025
n/a
Feb 2025
n/a
Nov 2024
n/a
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
1.57x
P/E over trailing EPS growth of 12%: four quarters to 2026-08-31 against the four to 2025-08-31
PEG, trailing ACN
FY Aug 2026
1.21x
FY Aug 2025
3.40x
FY Aug 2024
4.88x
FY Aug 2023
53.66x
FY Aug 2022
1.58x
Aug 2026
1.21x
May 2026
n/a
Feb 2026
20.70x
Nov 2025
13.68x
Aug 2025
3.40x
May 2025
1.68x
Feb 2025
2.94x
Nov 2024
2.90x
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
ACN ranks highest on profitability (84th percentile) and financial health (69th), and lowest on insider conviction (13th), among Services peers.
Profitability
84
Inputs
Return on equity+26.7% · 83 pct, sector of 207
Return on assets+12.0% · 87 pct, sector of 269
Return on invested capital+29.1% · 79 pct, sector of 81
Return on capital employed+23.7% · 89 pct, sector of 203
Financial health
69
Inputs
Debt to equity0.32x · 52 pct, sector of 228
Cash flow to debt1.22x · 85 pct, sector of 199
Growth
60
Inputs
Revenue growth, YoY+6.5% · 54 pct, sector of 341
Backlog growth, YoY+8.8% · 66 pct, sector of 77
Insider conviction
13
Inputs
Net Form 4 buying (codes P and S), 180d-$4.0M · 26 pct, sector of 174
Insider buyers, 180d0 · 0 pct, sector of 179
Institutional and government
61
Inputs
Funds adding, latest quarter963 · 99 pct, sector of 243
Congress net buyers, 365d-3 · 0 pct, sector of 37
Federal contracts, 180dno federal contracts in 180 days
Lobbying spend, 4 quarters$3.2M · 83 pct, sector of 61
Risk and compliance
40
Inputs
Short interest, % of float+3.3% · 46 pct, sector of 383
Recalls per $1B revenue, 3ynot measured for this sector, almost no peer has an event
EPA cases per $1B revenue, 5ynot measured for this sector, almost no peer has an event
New text in Risk Factors, latest 10-K+15.4% · 35 pct, sector of 227
1 not measured: US patents
US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
ACN filings, in plain words
Are Accenture insiders buying or selling ACN?
In the 180 days to 2026-10-27, Accenture insiders were net sellers, a net $4.6M across purchases and sales reported on Form 4, by 6 sellers.
Have members of Congress traded ACN?
Yes. In the year to 2026-10-27, 3 House members disclosed buying ACN and 6 House members disclosed selling it; the latest on record is a purchase by Scott Scott Franklin dated 2026-08-26.
Are there planned insider sales of ACN?
Yes. 5 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-27, covering $3.8M of stock; the latest, by Burgum Melissa A, was filed 2026-10-22.
Read the full summary
In the 180 days to 2026-10-27, Accenture insiders were net sellers of ACN, a net $4.6M across purchases and sales reported on Form 4 by 6 sellers. 37% of the 19 insider sales were made under a Rule 10b5-1 plan; the rest were not flagged as planned. In the year to 2026-10-27, 3 members of Congress disclosed buying ACN and 6 members disclosed selling it; the latest on record is a purchase by Scott Scott Franklin dated 2026-08-26. Insiders filed 5 Form 144 notices of intent to sell in the 90 days to 2026-10-27, covering $3.8M of stock. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
No password to create and no card required. We store your email address, your watchlist and your preferences, nothing else.
PRIVACY & COOKIES
We track filings, not you.
Essential cookies keep you signed in and remember this choice.
Google Analytics 4 and Microsoft Clarity load only if you allow them here; they
count visits and record how pages are used. We run no advertising and never sell
data. Details in the privacy policy. Change this any time
via "Cookie settings" in the footer.